About 190 results

ALLMedicine™ Acneiform Eruptions Center

Research & Reviews  54 results

Acneiform Eruption Following Elexacaftor-Tezacaftor-Ivacaftor Treatment in Patients Wit...
JAMA Dermatology; Okroglic L, Sohier P et. al.

Dec 1st, 2022 - A new treatment for cystic fibrosis combining 3 CFTR modulators-elexacaftor (ELX), tezacaftor (TEZ), and ivacaftor (IVA)-has recently been approved for cystic fibrosis treatment. The cutaneous adverse effects following treatment with this combinat...

Prognostic  factors for the development of acneiform eruptions in patients on epidermal...
Journal of the American Academy of Dermatology; Bierbrier R, D'Aguanno K et. al.

Oct 14th, 2022 - Prognostic  factors for the development of acneiform eruptions in patients on epidermal growth factor receptor inhibitors.|2022|Bierbrier R,D'Aguanno K,Kasymjanova G,Dell'Aniello S,Agulnik J,|

A real-world study of low-dose thalidomide in severe erythema nodosum leprosum highligh...
International Journal of Dermatology; Bathula S, Sardana K et. al.

Aug 5th, 2022 - Corticosteroids remain the main therapy in erythema nodosum leprosum (ENL), and long-term usage in chronic or recurrent ENL is a cause of significant morbidity and mortality. Thalidomide exerts dramatic effect in controlling ENL and helps reduce t...

Successful treatment of a child with MEK inhibitor-induced acneiform eruption with low-...
Pediatric Dermatology; Gupta R, Craddock MF

Jul 28th, 2022 - Selumetinib is a mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitor (MEKi) approved to treat inoperable plexiform neurofibromas and used off-label for low-grade gliomas. Acneiform eruptions are a known complication of...

Acneiform eruptions with combination targeted cancer therapy in colorectal cancer patie...
Supportive Care in Cancer : Official Journal of the Multi... Ibraheim MK, Lo J et. al.

Jul 1st, 2022 - Epidermal growth factor receptor inhibitors (EGFRI) can be used with pathway inhibitors, including mitogen-activated protein kinase kinase inhibitors (MEKIs), BRAF inhibitors (BRAFIs), and checkpoint inhibitors such as programmed death-ligand 1 (P...

see more →

Drugs  4 results see all →

Clinicaltrials.gov  2 results

Timolol for the Treatment of Acne and Rosacea

Nov 11th, 2021 - Rosacea affects roughly 16 million Americans who desire better treatments than those currently available. Acne vulgaris, another chronic inflammatory skin disorder, mainly affects teenagers but also affects 20-40% of adults. Investigating potentia...

Doxycycline vs Isotretinoin for Acneiform Eruptions of TKI

Sep 8th, 2021 - Background and Study Aims: Tyrosine Kinase inhibitors (TKIs) have become standard of care in patients with EGFR mutations in non-small cell lung cancer and other EGFR-mutated cancers. However, TKIs are well-known to cause cutaneous adverse events,...

see more →

News  16 results

Acneiform Eruptions More Severe With Targeted Therapy Combos

Jun 3rd, 2022 - The study covered in this summary was published on researchsquare.com as a preprint and has not yet been peer reviewed. Key Takeaway Acneiform eruptions in patients with colorectal cancer are more extensive and severe when targeted cancer therapie...

Treatment-Related Dermatologic AEs in Melanoma Require Careful Management

Oct 6th, 2021 - Tracey Liebman, MD Optimal management of treatment-related dermatologic adverse events (AEs) in patients with melanoma is essential for proper care, according to Tracey Liebman, MD. For the patients who develop nonspecific rash, pruritus or itch...

Strategies to Minimize mTOR-Related Dermatologic Adverse Events

Dec 5th, 2020 - Mario E. Lacouture, MD Many patients being treated with mTOR inhibitors experience dermatologic-related adverse events. Dermatologic side effects can have a psychosocial effect on patients, by affecting areas of the body exposed to other peop...

Skin Reactions Common in Children on MEKI/BRAFI, Preventive Care Urged

Jul 30th, 2020 - NEW YORK (Reuters Health) - Skin reactions are common in youngsters on MEKI/BRAFI therapy, often resulting in alterations or interruptions in cancer therapy, according to a multicenter retrospective study. "Every child in our study developed at le...

Subungual Hemorrhage From an Epidermal Growth Factor Receptor Inhibitor
Josh A. Hammel, MD, Dean Elhag, MD et. al.

Jan 27th, 2020 - To the Editor: The epidermal growth factor receptor (EGFR) signaling pathway plays a role in the differentiation, proliferation, and survival of several cell types. 1 Erlotinib is an EGFR inhibitor that targets aberrant cells that overexpress this.

see more →